Posted in Constellation in the News, Newsroom
Cambridge, MA – December 23, 2009 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it is selected as one of twenty-eight life sciences companies to participate in $25 million in Tax Incentives awarded by the Massachusetts Life Sciences [...]
Read more »
Posted in Constellation in the News, Newsroom
Recognized for Leading Innovation in Biotechnology Cambridge, MA, October 8, 2009 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has been chosen by AlwaysOn as one of the OnDC Top 100 Winners. Inclusion in the OnDC 100 [...]
Read more »
Posted in Constellation in the News, Newsroom
Company Leading Emerging Field of Epigenetics CAMBRIDGE, MA – September, 9, 2009 – Constellation Pharmaceuticals, Inc. today announced that it has appointed Edward E. Harlow, Jr., Ph.D. as the company’s Chief Scientific Officer. This appointment reflects the Company’s strong scientific heritage and its progress in building the leading biopharmaceutical effort focused on discovering and developing [...]
Read more »
Posted in Constellation in the News, Newsroom
Company’s Scientific Leaders Recognized for Outstanding Contributions in Cancer Research- CAMBRIDGE, MA – November 23, 2009 – Constellation Pharmaceuticals, Inc., today announced that the American Cancer Society has awarded the Medal of Honor to Edward E. Harlow, Jr., Ph.D., the company’s Chief Scientific Officer, and Arnold J. Levine, Ph.D., a member of the company’s Scientific [...]
Read more »
Posted in Constellation in the News, Newsroom
CAMBRIDGE, MA – August 13, 2009 – Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has appointed Mark A. Goldsmith, M.D., Ph.D., as Chief Executive Officer and Director of the company. Additionally, the company closed $17.2 million in [...]
Read more »
